PT2560662T - Sulodexide para a utilização no tratamento de patologias nas quais as metaloproteínases estão envolvidas - Google Patents

Sulodexide para a utilização no tratamento de patologias nas quais as metaloproteínases estão envolvidas

Info

Publication number: PT2560662T
Authority: PT; Portugal
Prior art keywords: sulodexide; metalloproteinases; pathologies; involved; treatment
Prior art date: 2010-04-23

Application number

PT117236521T

Other languages

English (en)

Inventor

Claudio Viscomi Giuseppe

Mannello Ferdinando

Bruno Cristiana

Original Assignee

Alfa Wassermann Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-04-23

Filing date

2011-04-20

Publication date

2017-07-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43063923&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2560662(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-04-20 Application filed by Alfa Wassermann Spa filed Critical Alfa Wassermann Spa

2017-07-10 Publication of PT2560662T publication Critical patent/PT2560662T/pt

Links

GRYSXUXXBDSYRT-WOUKDFQISA-N (2r,3r,4r,5r)-2-(hydroxymethyl)-4-methoxy-5-[6-(methylamino)purin-9-yl]oxolan-3-ol Chemical compound C1=NC=2C(NC)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1OC GRYSXUXXBDSYRT-WOUKDFQISA-N 0.000 title 1
102000005741 Metalloproteases Human genes 0.000 title 1
108010006035 Metalloproteases Proteins 0.000 title 1
229920000439 Sulodexide Polymers 0.000 title 1
230000007170 pathology Effects 0.000 title 1
229960003491 sulodexide Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/38—Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Dermatology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Cell Biology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Developmental Biology & Embryology (AREA)
Communicable Diseases (AREA)
Hematology (AREA)
Diabetes (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Oncology (AREA)
Immunology (AREA)
Virology (AREA)
Zoology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Enzymes And Modification Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

PT117236521T 2010-04-23 2011-04-20 Sulodexide para a utilização no tratamento de patologias nas quais as metaloproteínases estão envolvidas PT2560662T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
ITBO2010A000250A IT1401253B1 (it)	2010-04-23	2010-04-23	Uso del sulodexide per la riduzione delle metalloproteinasi di matrice.

Publications (1)

Publication Number	Publication Date
PT2560662T true PT2560662T (pt)	2017-07-10

Family

ID=43063923

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PT117236521T PT2560662T (pt)	2010-04-23	2011-04-20	Sulodexide para a utilização no tratamento de patologias nas quais as metaloproteínases estão envolvidas
PT13161007T PT2609925T (pt)	2010-04-23	2011-04-20	Sulfato de dermatano para utilização no tratamento de patologias em que estão envolvidos metaloproteinases

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PT13161007T PT2609925T (pt)	2010-04-23	2011-04-20	Sulfato de dermatano para utilização no tratamento de patologias em que estão envolvidos metaloproteinases

Country Status (11)

Country	Link
US (1)	US8987231B2 (pt)
EP (2)	EP2560662B1 (pt)
KR (2)	KR20160060164A (pt)
CN (1)	CN102883728A (pt)
ES (2)	ES2628582T3 (pt)
IT (1)	IT1401253B1 (pt)
MX (1)	MX339537B (pt)
PL (2)	PL2560662T3 (pt)
PT (2)	PT2560662T (pt)
RU (1)	RU2557996C2 (pt)
WO (1)	WO2011132161A2 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ITMI20061692A1 (it)	2006-09-05	2008-03-06	Alfa Wassermann Spa	Uso di polioli per ottenere forme polimorfe stabili di rifaximina
CA2926888C (en) *	2013-10-22	2020-03-24	Cell Receptor Sa	Modulation of the physical interaction between platelets and the cell surface effecting cell proliferation
CN104398533B (zh) *	2014-11-26	2017-03-08	山东辰中生物制药有限公司	舒洛地特的生产方法
RU2667650C1 (ru) *	2017-12-15	2018-09-21	Федеральное государственное бюджетное образовательное учреждение высшего образования "Самарский государственный медицинский университет" Министерства здравоохранения Российской Федерации	Способ лечения и профилактики острого тромбоза геморроидальных узлов

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2426586A1 (de)	1973-06-14	1975-01-09	Opocrin Srl	Verfahren zur herstellung von glukuronil-glukosamin-glykan-sulfaten mit antilipaemischer wirkung
US4705798A (en)	1985-09-27	1987-11-10	University Of Iowa Research Foundation	Phenylephrine prodrug useful as mydriatic agent
GB8827305D0 (en)	1988-11-23	1988-12-29	British Bio Technology	Compounds
IT1242604B (it) *	1990-11-13	1994-05-16	Alfa Wassermann Spa	Sali di glicosaminoglicani con esteri di aminoacidi, loro preparazione e formulazioni farmaceutiche che li contengono.
IT1245907B (it) *	1991-05-17	1994-10-25	Alfa Wassermann Spa	Uso dei glicosaminoglicani nel trattamento della nefropatia diabetica e della neuropatia diabetica.
GB9215665D0 (en)	1992-07-23	1992-09-09	British Bio Technology	Compounds
US5455258A (en)	1993-01-06	1995-10-03	Ciba-Geigy Corporation	Arylsulfonamido-substituted hydroxamic acids
PL177218B1 (pl) *	1993-09-30	1999-10-29	Seikagaku Kogyo Co Ltd	Siarczany dermatanu oraz środki przeciwzakrzepowe zawierające siarczany dermatanu
IT1274351B (it) *	1994-10-06	1997-07-17	Alfa Wassermann Spa	Uso di alcuni glicosaminoglicani nella dialisi peritoneale.
CA2238306A1 (en)	1995-12-08	1997-06-12	Agouron Pharmaceuticals, Inc.	Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation
IT1285546B1 (it) *	1996-01-16	1998-06-18	Alfa Wassermann Spa	Uso del dermatano solfato a basso peso molecolare e delle specialita' medicinali che lo contengono nella terapia e nella prevenzione della
IT1299969B1 (it) *	1998-04-15	2000-04-04	Alfa Wassermann Spa	Uso di sulodexide e delle specialita' medicinali che lo contengono nel trattamento della retinopatia diabetica.
DE69833822D1 (de)	1998-10-01	2006-05-11	Giovanni Gambaro	Substanzen zur Vorbeugung von krankhafter TGF-beta Überexpression und Methoden derer Ermittlung
US20040009952A1 (en)	1998-10-19	2004-01-15	Giovanni Gambaro	TGF-beta gene overexpression preventing substances for the treatment of disorders connected with pathological overexpression of TGF-beta
IL127896A0 (en)	1998-12-31	1999-10-28	Gail Laster	A novel treatment for preeclampsia and related diseases
US20090325876A1 (en) *	2004-09-29	2009-12-31	Saul Yedgar	Use of lipid conjugates in the treatment of diseases associated with vasculature
US7259152B2 (en)	2000-06-07	2007-08-21	Alfa Wasserman, Inc.	Methods and compositions using sulodexide for the treatment of diabetic nephropathy
AU2002221935A1 (en)	2000-12-16	2002-06-24	Aventis Pharma Deutschland Gmbh	Use of low molecular heparin for treating osteoarthritis
FR2864087B1 (fr)	2003-12-19	2006-01-27	Aventis Pharma Sa	Derives carboxy-reduits du dermatan sulfate, leur preparation, leur application comme medicament et les compositions pharmaceutiques les renfermant
KR100808131B1 (ko) *	2006-06-22	2008-02-29	부경대학교 산학협력단	인간 섬유육종 세포에서 메트릭스 메탈로프로테이나제-9의발현을 억제시키는 카복실화 키토올리고사카라이드 화합물및 이를 함유한 메트릭스 메탈로프로테이나제-9 억제제
CN101632686A (zh) *	2008-04-04	2010-01-27	马斯特里赫特大学	糖胺聚糖用于修复糖萼的用途
GB0919054D0 (en)	2009-10-30	2009-12-16	Isis Innovation	Treatment of obesity

2010
- 2010-04-23 IT ITBO2010A000250A patent/IT1401253B1/it active
2011
- 2011-04-20 EP EP11723652.1A patent/EP2560662B1/en not_active Revoked
- 2011-04-20 MX MX2012012285A patent/MX339537B/es active IP Right Grant
- 2011-04-20 WO PCT/IB2011/051726 patent/WO2011132161A2/en not_active Ceased
- 2011-04-20 EP EP13161007.3A patent/EP2609925B1/en not_active Not-in-force
- 2011-04-20 CN CN201180020126XA patent/CN102883728A/zh active Pending
- 2011-04-20 PT PT117236521T patent/PT2560662T/pt unknown
- 2011-04-20 KR KR1020167013025A patent/KR20160060164A/ko not_active Ceased
- 2011-04-20 PT PT13161007T patent/PT2609925T/pt unknown
- 2011-04-20 PL PL11723652T patent/PL2560662T3/pl unknown
- 2011-04-20 RU RU2012142256/15A patent/RU2557996C2/ru active
- 2011-04-20 KR KR1020127027513A patent/KR101739757B1/ko active Active
- 2011-04-20 ES ES11723652.1T patent/ES2628582T3/es active Active
- 2011-04-20 US US13/642,510 patent/US8987231B2/en active Active
- 2011-04-20 PL PL13161007T patent/PL2609925T3/pl unknown
- 2011-04-20 ES ES13161007.3T patent/ES2694587T3/es active Active

Also Published As

Publication number	Publication date
MX339537B (es)	2016-05-30
RU2557996C2 (ru)	2015-07-27
IT1401253B1 (it)	2013-07-18
EP2560662B1 (en)	2017-06-07
KR20160060164A (ko)	2016-05-27
US8987231B2 (en)	2015-03-24
EP2560662A2 (en)	2013-02-27
ES2628582T3 (es)	2017-08-03
PT2609925T (pt)	2018-11-22
US20130045946A1 (en)	2013-02-21
CN102883728A (zh)	2013-01-16
EP2609925A3 (en)	2013-09-04
WO2011132161A3 (en)	2012-03-08
EP2609925A2 (en)	2013-07-03
MX2012012285A (es)	2012-11-23
WO2011132161A2 (en)	2011-10-27
EP2609925B1 (en)	2018-10-17
ES2694587T3 (es)	2018-12-21
RU2012142256A (ru)	2014-05-27
PL2560662T3 (pl)	2017-09-29
PL2609925T3 (pl)	2019-02-28
ITBO20100250A1 (it)	2011-10-24
KR101739757B1 (ko)	2017-05-25
KR20130072199A (ko)	2013-07-01

Publication	Publication Date	Title
GB201115711D0 (en)	2011-10-26	Phyto-cannabinoids for use in the treatment of cancer
GB2524689B (en)	2016-01-27	Cannabinoids for use in the treatment of neuropathic pain
ZA201207574B (en)	2014-09-25	Phytocannabinoids in the treatment of cancer
SG10201506840QA (en)	2015-10-29	Cytotoxicity-inducing therapeutic agent
PL2652193T3 (pl)	2021-01-25	Obróbka
IL275350B (en)	2021-07-29	Treatment of neoplastic diseases
SG2014014724A (en)	2014-07-30	METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS
PT2694107T (pt)	2018-11-27	Tratamento para patologias dermatológicas
GB2496688B (en)	2016-06-29	Tetrahydrocannabivarin for use in the treatment of intestinal inflammatory diseases
IL225896A0 (en)	2013-06-27	Treatment of mecp-2 related disorders
ZA201500547B (en)	2017-09-27	Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases
ZA201305970B (en)	2014-04-30	Arylosulfonami for the treatment of cns diseases
IL232239A0 (en)	2014-06-30	Medical use
ZA201307058B (en)	2015-08-26	Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment
PT2560662T (pt)	2017-07-10	Sulodexide para a utilização no tratamento de patologias nas quais as metaloproteínases estão envolvidas
GB201013573D0 (en)	2010-09-29	Treatment
GB201016486D0 (en)	2010-11-17	Compounds for the use in treatment of plants
GB201718726D0 (en)	2017-12-27	Phytocannabinoids in the treatment of cancer
HK1181301A (en)	2013-11-08	Sulodexide for use in the treatment of pathologies wherein metalloproteinases are involved
PL2456445T3 (pl)	2014-10-31	Środek do leczenia chorób skóry
GB201014097D0 (en)	2010-10-06	Treatment
GB201013068D0 (en)	2010-09-15	Liquid treatment
GB201105302D0 (en)	2011-05-11	Treatment of acidosis
GB201001659D0 (en)	2010-03-17	Body treatment product
HUP1000688A2 (en)	2012-08-28	Use of trifluoro-phthalimides in the treatment of cancer